APR 22, 2020 9:37 AM PDT

This model predicts those at high risk of pancreatic cancer

A new study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, highlights a model capable of predicting those at high risk of pancreatic cancer. The model offers an alternative screening technique that could be tailored to individuals.

"Pancreatic cancer is a particularly deadly cancer, with about 80 percent of patients diagnosed with advanced, incurable disease," says author Peter Kraft, PhD, who is a professor of epidemiology at the Harvard T.H. Chan School of Public Health in Boston. "Catching it at an earlier stage makes it more likely that surgery will be an option, increasing the chances of survival."

In conducting this study, Kraft and his fellow colleagues were interested in cumulatively analyzing the risk factors for pancreatic cancer. Known factors include family history, chronic conditions like diabetes and pancreatitis, and smoking, in addition to particular circulating biomarkers associated with insulin resistance. "These factors have been investigated individually, and in this study, we wanted to examine the combined effect of clinical factors, common genetic predisposition variants, and circulating biomarkers."

To do so, they analyzed data from over 1,500 people in four large prospective cohort studies: the Health Professionals Follow-up Study; the Nurses' Health Study; the Physicians' Health Study; and the Women's Health Initiative. From this data, they considered lifestyle and clinical characteristics, blood samples, and genomic DNA from peripheral blood leukocytes of the participants.

Photo: Pixabay

They then developed three relative risk models for men and women separately. As reported in Eureka Alert, “One featured only clinical factors; one added the weighted genetic risk score to the clinical factors; and the third added biomarkers proinsulin, adiponectin, IL-6, and total branched-chain amino acids.”

The researchers recognize that their results must be verified by future studies. Furthermore, they acknowledge that their study had significant limitations because it only considered U.S. non-Hispanic white participants. Nevertheless, Kraft comments that their results show that there is value in combining biomarkers with clinical and genetic factors.

"Like most cancers, pancreatic cancer is multifactorial," he said. "The more we are able to combine information from multiple domains, the better we will become at identifying those who could benefit from screening."

Sources: Cancer Epidemiology, Biomarkers & Prevention, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
APR 14, 2021
Clinical & Molecular DX
AI-Powered Imaging System Can Tell If a Patient Is Cancer-Free
APR 14, 2021
AI-Powered Imaging System Can Tell If a Patient Is Cancer-Free
A patient undergoes chemotherapy and radiation for rectal cancer. How do doctors know whether all the malignant tissue h ...
APR 11, 2021
Genetics & Genomics
Trial Shows Personalized Cancer Vaccines are Safe
APR 11, 2021
Trial Shows Personalized Cancer Vaccines are Safe
Vaccines are mostly known as tools to prevent illness. But cancer vaccines are a bit different, and aim to treat existin ...
APR 04, 2021
Drug Discovery & Development
Ion-Pump for Chemotherapy
APR 04, 2021
Ion-Pump for Chemotherapy
Patients of malignant brain tumors experience recurrences even after subsequent treatments. To address this issue, scien ...
MAY 18, 2021
Cancer
New guidelines change screening age for colorectal cancer to 45
MAY 18, 2021
New guidelines change screening age for colorectal cancer to 45
Following new guideline changes from the U.S. Preventive Services Task Force (USPSTF), individuals with an average risk ...
JUL 13, 2021
Clinical & Molecular DX
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
JUL 13, 2021
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
Researchers have developed the first diagnostic “pen” that acts as a guide for surgeons, helping them distin ...
JUL 16, 2021
Drug Discovery & Development
Machine Learning Ranks Cancer Drugs by Efficacy
JUL 16, 2021
Machine Learning Ranks Cancer Drugs by Efficacy
A machine learning algorithm developed by researchers at the Queen Mary University of London in the UK can rank cancer d ...
Loading Comments...